BVd therapy significantly prolonged progression-free survival compared to DVd in patients with relapsed or refractory multiple myeloma. It was associated with a higher rate of complete response and minimal residual disease negativity. The treatment resulted in higher adverse events, particularly ocular complications, compared to DVd.
Study
|
Phase 3, open-label, randomized trial [DREAMM-7] |
| Relapsed or refractory multiple myeloma after at least one line of therapy |
| Belantamab mafodotin – bortezomib – dexamethasone (BVd, n=243) vs daratumumab – bortezomib – dexamethasone (DVd, n=251)
|
Efficacy
|
CR or better + MRD-negative: 25% vs 10% |
| mPFS: 36.6 mos vs 13.4 mos (BVd vs. DVd, HR 0.41 [0.31-0.53], p<0.001) |
| OS at 18 mos: 84% vs 73%
|
Safety
|
Grade >=3 AEs: 95% vs 78% |
| Serious AEs: 50% vs 37% |
| Ocular events (any grade): 79% vs 29% |
| Thrombocytopenia (69% vs 50%)
|
N Engl J Med 2024;391:393-407
Hungria V, Robak P, Hus M New Reference: Belantamab for Multiple Myeloma
http://doi.org/10.1056/NEJMoa2405090
Reviewed by Ulas D. Bayraktar, MD on Nov 6, 2025
